In the present work, we examined methylation levels of the CTNNA1 promoter using quantitative methylation-specific PCR method in bone marrow samples from 319 AML patients, with the aim of identifying a subset of patients who harbored aberrant methylation levels and comparing the clinical characteristics of these patients. This evidence concerns the gene CTNNA1 and acute myeloid leukemia.